Jneid et al 2012 UA/NSTEMI Focused Update 905 Appendix 3. Dosing Table for Antiplatelet and Anticoagulant Therapy Discussed in This Focused Update to Support PCI in UA/NSTEMI Drug* During PCI Comments All Patients to Receive ASA Patient Received Initial Medical Treatment (With a P2Y12 Receptor Inhibitor) Patient Did Not Receive Initial Medical Treatment (With a P2Y12 Receptor Inhibitor) Glycoprotein IIb/IIIa Receptor Antagonists Abciximab Of uncertain benefit LD of 0.25 mg/kg IV bolus MD of 0.125 mcg/kg per min (maximum 10 mcg/min) (Class I, LOE: A) Continue for up to 12 h at the discretion of the physician. Eptifibatide Of uncertain benefit LD of 180 mcg/kg IV bolus followed 10 min later by second IV bolus of 180 mcg/kg MD of 2.0 mcg/kg per min, started after first bolus; reduce infusion by 50% in patients with estimated creatinine clearance 50 mL/min (Class I, LOE: A) Double bolus is recommended to support PCI in STEMI as the recommended adult dosage of eptifibatide in patients with normal renal function. Infusion should be continued for 12 to 18 h at the discretion of the physician. Tirofiban Of uncertain benefit LD of 25 mcg/kg IV bolus MD of IV infusion of 0.15 mcg/kg per min; reduce rate of infusion by 50% in patients with estimated creatinine clearance 30 mL/min (Class I, LOE: B) Increased dosing over previous recommendation. Continue for up to 18 h at the discretion of the physician. 